Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin versus placebo in neonates and young infants with Prader-Willi syndrome
NL-OMON55101Phase 3Withdrawn
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Oxytocin with Placebo (2 arms). Primary endpoint: Responder rate on Neonatal Oral-Motor Assessment Scale at 4 weeks. Planned start Sep 2020; status: withdrawn.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NL-OMON55101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55101.